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Lipinski-Rule of FiveAbstract A series of 16 N1-(3-chloro-4-ﬂuorophenyl)-N4-substituted semicarbazone derivatives
were synthesized and subjected to computational pharmacokinetic studies to predict molecular
properties. All the title compounds (4a–p) followed the Lipinski ‘‘Rule of Five’’. The synthesized
compounds were characterized by elemental analyses and spectral data and the compounds
(4a–p) were evaluated for antimicrobial activities. Among them the compound 2-(4-hydroxybenzy-
lidene)-N-(3-chloro-4-ﬂuorolphenyl)hydrazinecarboxamide (4f) was found to be the most active
compound that showed good antibacterial activity while the compound 2-(4-methoxybenzyli-
dene)-N-(3-chloro-4-ﬂuorolphenyl)hydrazinecarboxamide (4g) was moderately active against fun-
gal strains. We have noticed that the compounds, (4f, 4k and 4d) bearing OH and NO2 groups
on the phenyl ring at position 4 exhibited good antibacterial activity while compound (4g) bearing
OCH3 on the phenyl ring at position 4 exhibited moderate antifungal activity.
ª 2011 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
A wide variety of antibiotics have been developed to combat
against bacterial infections. After years of extensive overuse
or misuse of antibiotics, bacteria are becoming antibiotic resis-
tant resulting in growing threat to human health around the
world. Antibacterial resistance is a cause of increased mortality
(Mohamed et al., 2004). Fungal infections like Candidiasis,
Cryptococcosis and Aspergillosis are more common in immu-
no-compromised patients (Spratt, 1994). Life threatening
infectious disease caused by multidrug-resistant Gram-positive
S862 M.J. Ahsan et al.and -negative pathogenic bacteria increased to an alarming le-
vel around the world. Owing to this increased microbial resis-
tance, new classes of antimicrobial agents with novel
mechanisms are today’s need to combat multidrug-resistant
infections. Semicarbazones were found to possess different
biological activities, such as anticonvulsant (Yogeeswari
et al., 2005), antitubercular (Sriram et al., 2004), anticancer
(Afrasiabi et al., 2005), antimicrobial (Kasuga et al., 2001),
etc. Therefore, in the current work we have focussed on the
syntheses of some semicarbazones and their antibacterial and
antifungal activities. Earlier we reported the anticonvulsant
activity of semicarbazone derivatives (Amir et al., 2010).
2. Molecular properties prediction
Molecular properties, mainly hydrophobicity, molecular size,
ﬂexibility and the presence of various pharmacophoric features
inﬂuence the behavior of molecules in the living organism,
including bioavailability. Thus in order to achieve good oral
drugs we have subjected a series of semicarbazone derivatives
(4a–p) for the prediction of lipophilicity, solubility and Lipinski
‘‘Rule of Five’’ and other properties for ﬁltering compounds for
antimicrobial screening.
2.1. Lipophilicity
All the compounds were subjected to computational study in
order to ﬁlter the drugs for antimicrobial screening. For good
membrane permeability logP value should be 65 (Lipinski
et al., 1997). All the title compounds (4a–p) have logP value
3.44–5.467.
2.2. Absorption, polar surface area, and ‘‘Rule of Five’’
properties
Good intestinal absorption, reduced molecular ﬂexibility
(measured by the number of rotatable bonds), low polar sur-
face area or total hydrogen bond count (sum of donors and
acceptors) are important predictors of good oral bioavailabil-
ity (Veber et al., 2002; Refsgaard et al., 2005). Membrane
permeability and bioavailability are always associated with
some basic molecular descriptors such as logP (partition
coefﬁcient), molecular weight (MW), or hydrogen bond
acceptors and donors’ counts in a molecule. Number of
rotatable bonds is important for conformational changes of
molecules under study and ultimately for the binding of
receptors or channels. It is revealed that for passing oral bio-
availability criteria, the number of rotatable bond should be
610 (Veber et al., 2002). The compounds in this series (4a–p)
in general possess sufﬁcient number of rotatable bonds (3–5)
and therefore, exhibit good conformational ﬂexibility. Molec-
ular polar surface area (TPSA) is a very useful parameter for
the prediction of drug transport properties. TPSA is a sum
of surfaces of polar atoms (usually oxygen, nitrogen and at-
tached hydrogen) in a molecule. TPSA and volume are inver-
sely proportional to %ABS. TPSA was used to calculate the
percentage of absorption (%ABS) according to the equation:
%ABS = 109 ± 0.345 · TPSA (Wang et al., 1997). From all
these parameters, it can be observed that all the title com-
pounds exhibited a great %ABS ranging from 74% to
99%. The Lipinski ‘‘Rule of Five’’ states that the molecules
with good membrane permeability have logP 65, molecularweight 6500, number of hydrogen bond acceptors 610, and
number of hydrogen bond donors 65 (Lipinski et al., 1997).
This rule is widely used as a ﬁlter for drug-like properties.
All the title compounds (4a–p) followed the Lipinski ‘‘Rule
of Five’’. The pharmacokinetic parameters were calculated
online from Molinspiration Chemoinformatics (http://
www.molinspiration.com/cgi-bin/properties) and are given
in Table 1.3. Experimental
3.1. Instrumentation
The entire chemical reagents which are used in the study are
procured locally. The completion of reaction is monitored by
thin layer chromatography (TLC) using chloroform-methanol
(9:1) as the solvent system. The products were puriﬁed by
recrystallisation with absolute ethanol and purity of the com-
pounds was checked by thin layer chromatography (TLC)
using silica gel G plates (Merck). The spot was developed in
iodine chamber or viewed under UV lamp. Melting points
were determined in an open capillary using melting point appa-
ratus and are uncorrected. The proton magnetic resonance (1H
NMR) spectra were recorded on a Brucker 300 MHz instru-
ment in DMSOd6 using tetramethylsilane as an internal stan-
dard. The infrared spectra of compounds were recorded in
KBr on a Bio-Rad FTIR Spectro-photometer.
3.1.1. Procedure for the synthesis of 3-chloro-4-ﬂuorophenyl
urea (2)
3-Chloro-4-ﬂuoro aniline (0.1 mol, 14.65 g) was dissolved in
20 ml of glacial acetic acid and 80 ml of hot water. To this, a
solution of sodium cyanate (0.1 mol, 6.5 g) in 80 ml of hot
water was added with stirring. It was allowed to stand for
30 min, then cooled in ice bath and ﬁltered with suction, dried
and recrystallized from boiling water (Amir et al., 2010). The
purity of the compound was checked by TLC using chloro-
form-methanol (9:1) as the mobile phase. Yield 78%; m.p.
141–143 C, IR (KBr) cm1: 3374 (NAH), 1675 (C‚O); 1H
NMR (DMSO-d6) d ppm: 5.92 (s, 2H, NH2), 7.16–7.23 (m,
2H, aromatic), 7.72–7.74 (d, 1H, aromatic), d 8.69 (s, 1H,
ArH); MS: m/z 189 M++1. Anal. Calcd for C7H6ClFN2O:
C, 44.58; H, 3.21; N, 14.85. Found: C, 44.56; H, 3.22; N,
14.87.
3.1.2. Procedure for the synthesis of 3-chloro-4-ﬂourophenyl
semicarbazide (3)
A mixture of 3-chloro-4-ﬂuorophenyl urea 2 (0.05 mol, 9.45 g)
and hydrazine hydrate (0.05 mol, 2.5 ml) in ethanol were re-
ﬂuxed for 48 h with stirring. Two third volume of alcohol
was distilled by vacuum distillation and then poured into
crushed ice. The resultant precipitate was ﬁltered, washed with
water and dried. The solid was recrystallized from 50 ml of
90% ethanol. The purity of the compound was checked by
TLC using chloroform-methanol (9:1) as the mobile phase.
Yield 66%; m.p. 90–92 C, IR (KBr) cm1: 3372 (NAH),
1676 cm1 (C‚O); 1H NMR (DMSO-d6) d ppm: 5.96 (s,
2H, NH2), 7.20–7.76 (m, 3H, aromatic), 7.89 (s, 1H, Ar-
NH), d 8.88 (s, 1H, CONH); MS: m/z 204 M++1. Anal. Calcd
for C7H7ClFN3O: C, 41.29; H, 3.47; N, 20.64. Found: C,
41.31; H, 3.49; N, 20.66.
Table 1 Pharmacokinetic parameters important for good oral bioavailability of title compounds (4a–p).
Compd. % ABS Volume (A3) TPSA (A2) NROTB n-ON
acceptor
n-OHNH
donors
miLog P MW Lipinski’s
violations
Rule – – – – <10 <5 65 <500 61
4a 90.55 254.504 53.489 3 4 2 4.813 326 0
4b 90.55 254.504 53.489 3 4 2 4.861 326 0
4c 74.74 264.302 99.313 4 7 2 4.094 336 0
4d 74.74 264.302 99.313 4 7 2 4.142 336 0
4e 83.57 248.986 73.717 3 5 3 4.123 307 0
4f 83.57 248.986 73.717 3 5 3 3.704 307 0
4g 87.36 266.514 62.723 4 5 2 4.24 321 0
4h 84.17 292.059 71.957 5 6 2 3.829 351 0
4i 89.43 286.874 56.727 4 5 2 4.285 334 0
4j 90.55 268.04 53.489 3 4 2 5.467 360 1
4k 83.57 265.547 73.717 3 5 3 3.617 321 0
4l 87.36 283.075 62.723 4 5 2 4.153 335 0
4m 99.55 271.065 53.489 3 4 2 4.774 340 0
4n 74.74 280.863 99.313 4 7 2 4.055 350 0
4o 99.55 274.09 53.489 3 4 2 4.545 319 0
4p 86.01 222.536 66.629 3 5 2 3.44 281 0
%ABS, percentage of absorption; TPSA, topological polar surface area; NROTB, number of rotatable bonds; MW, molecular weight; miLogP,
logarithm of compound partition coefﬁcient between n-octanol and water; n-OHNH, number of hydrogen bond donors; n-ON, number of
hydrogen bond acceptors.
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ﬂuorophenyl)-N4-substituted semicarbazones (4a–p)
To a solution of 3-chloro-4-ﬂuorophenyl semicarbazide 2
(0.005 mol, 1.02 g) in 1 ml conc. HCl and 25 ml water was
added sodium acetate solution (0.005 mol, 0.41 g in 2 ml
water). About 25 ml ethanol was added to clear the turbidity.
This solution mixture was added to an equimolar quantity of
the appropriate aldehydes or ketones in alcohol. The solution
was stirred for 15 min immediately precipitation occurred, (if
immediate precipitation did not occurred, reaction mixture
was allowed to stand for 1–2 h.) and the solids were ﬁltered,
dried and recrystallized from hot ethanol. The completion of
reactions was monitored by TLC using chloroform-methanol
(9:1) as the mobile phase.3.1.3.1. 2-(2-Chlorobenzylidene)-N-(3-chloro-4-ﬂuorophenyl)
hydrazinecarboxamide (4a). Yield 72%; m.p. 178–180 C, IR
(KBr) cm1: 3375 (NAH), 1677 (C‚O), 1532 (C‚N); 1H
NMR (DMSO-d6) d ppm: 7.22–7.94 (m, 7H, aromatic), 7.94
(s, 1H, N‚CH), 9.19 (s, 1H, Ar–NH), 11.11 (s, 1H, CONH);
MS: m/z, M+ 325, M++1 326, M++2 327. Anal. Calcd for
C14H10Cl2FN3O: C, 51.56; H, 3.09; N, 12.88. Found: C,
51.57; H, 3.10; N, 12.87.
3.1.3.2. 2-(4-Chlorobenzylidene)-N-(3-chloro-4-ﬂuorophenyl)
hydrazinecarboxamide (4b). Yield 72%; m.p. 190–192 C, IR
(KBr) cm1: 3400 (NAH), 1694 (C‚O), 1536 (C‚N); 1H
NMR (DMSO-d6) d ppm: 7.02–7.84 (m, 7H, aromatic), 7.96
(s, 1H, N‚CH), 9.10 (s, 1H, Ar–NH), 11.13 (s, 1H, CONH);
MS: m/z, M+ 325, M++1 326, M++2 327. Anal. Calcd for
C14H10Cl2FN3O: C,51.56; H, 3.09; N, 12.88. Found: C,
51.57; H, 3.10; N, 12.87.
3.1.3.3. 2-(2-Nitrobenzylidene)-N-(3-chloro-4-ﬂuorophenyl)
hydrazinecarboxamide (4c). Yield 72%; m.p. 218–220 C, IR
(KBr) cm1: 3403 (NAH), 1690 (C‚O), 1526 (C‚N); 1HNMR (DMSO-d6) d ppm: 7.22–7.87 (m, 7H, aromatic), 7.99
(s, 1H, N‚CH), 9.20 (s, 1H, Ar-NH), 11.23 (s, 1H, CONH);
MS: m/z, M+ 336, M++1 337, M++2 338. Anal. Calcd for
C14H10ClFN4O3: C, 49.94; H, 2.99; N, 16.64. Found: C,
49.94; H, 3.00; N, 16.66.3.1.3.4. 2-(4-Nitrobenzylidene)-N-(3-chloro-4-ﬂuorophenyl)
hydrazinecarboxamide (4d). Yield 68%; m.p. 198–200 C, IR
(KBr) cm1: 3403 (NAH), 1690 (C‚O), 1526 (C‚N); 1H
NMR (DMSO-d6) d ppm: 7.02–7.67 (m, 7H, aromatic), 7.89
(s, 1H, N‚CH), 9.19 (s, 1H, Ar–NH), 11.43 (s, 1H, CONH);
MS: m/z, M+ 336, M++1 337, M++2 338. Anal. Calcd for
C14H10ClFN4O3: C, 49.94; H, 2.99; N, 16.64. Found: C,
49.94; H, 3.00; N, 16.66.
3.1.3.5. 2-(2-Hydroxybenzylidene)-N-(3-chloro-4-ﬂuorophenyl)
hydrazinecarboxamide (4e). Yield 58%; m.p. 173–175 C, IR
(KBr) cm1: 3375 (NAH), 1676 (C‚O), 1536 (C‚N);
(DMSO-d6) d ppm: 7.22–8.38 (m, 7H, aromatic), 8.48 (s, 1H,
N‚CH), 9.15 (s, 1H, Ar–NH), 10.60 (s, 1H, Ar-OH), 11.18
(s, 1H, CONH); MS: m/z, M+ 307, M++1, 308, M++2,
309; Anal. Calcd for C14H11ClFN3O2: C, 54.65; H, 3.60; N,
13.66. Found: C, 54.67; H, 3.59; N, 13.65.
3.1.3.6. 2-(4-Hydroxybenzylidene)-N-(3-chloro-4-ﬂuorophenyl)
hydrazinecarboxamide (4f). Yield 68%; m.p. 202–204 C, IR
(KBr) cm1: 3370 (NAH), 1678 (C‚O), 1536 (C‚N);
(DMSO-d6) d ppm: 6.79–7.95 (m, 7H, aromatic), 7.97 (s, 1H,
N‚CH), 9.02 (s, 1H, Ar–NH), 9.85 (s, 1H, CONH), 10.67
(s, 1H, Ar-OH); MS: m/z, M+ 307, M++1, 308, M++2,
309; Anal. Calcd for C14H11ClFN3O2: C, 54.65; H, 3.60; N,
13.66. Found: C, 54.66; H, 3.60; N, 13.67.
3.1.3.7. 2-(4-Methoxybenzylidene)-N-(3-chloro-4-ﬂuorophenyl)
hydrazinecarboxamide (4g). Yield 70%; m.p. 148–150 C, IR
(KBr) cm1: 3360 (NAH), 1688 (C‚O), 1546 (C‚N);
S864 M.J. Ahsan et al.(DMSO-d6) d ppm: 3.75 (s, 3H. OCH3), 6.79–7.90 (m, 7H, aro-
matic), 7.98 (s, 1H, N‚CH), 9.08 (s, 1H, Ar–NH), 11.05 (s,
1H, CONH); MS: m/z, M+ 321, M++1, 322, M++2, 323;
Anal. Calcd for C15H13ClFN3O2: C, 56.00; H, 4.07; N,
13.06. Found: C, 56.03; H, 4.10; N, 13.07.
3.1.3.8. 2-(3,4-Dimethoxybenzylidene)-N-(3-chloro-4-ﬂuoro-
phenyl)hydrazinecarboxamide (4h). Yield 70%; m.p. 192–
194 C, IR (KBr) cm1: 3370 (NAH), 1678 (C‚O), 1576
(C‚N); (DMSO-d6) d ppm: 3.80 (s, 6H. (OCH3)2), 6.80–7.91
(m, 6H, aromatic), 7.90 (s, 1H, N‚CH), 9.09 (s, 1H, Ar-
NH), 11.00 (s, 1H, CONH); MS: m/z M+ 351, M++1, 352,
M++2, 353; Anal. Calcd for C16H15ClFN3O3: C, 54.63; H,
4.30; N, 11.95. Found: C, 54.63; H, 4.32; N, 11.96.
3.1.3.9. 2-(4,N,N-Dimethylaminobenzylidene)-N-(3-chloro-4-
ﬂuorophenyl)hydrazinecarboxamide (4i). Yield 74%; m.p.
182–184 C, IR (KBr) cm1: 3366 (NAH), 1678 (C‚O),
1538 (C‚N); (DMSO-d6) d ppm: 2.96 (s, 6H, N(CH3)2),
6.70–7.82 (m, 7H, aromatic), 7.97(s, 1H, N‚CH), 9.01 (s,
1H, Ar–NH), 10.59 (s, 1H, CONH); MS: m/z, M+ 334,
M++1, 335, M++2, 336; Anal. Calcd for C16H16ClFN4O:
C, 57.40; H, 4.82; N, 16.74. Found: C, 57.42; H, 4.81; N, 16.72.
3.1.3.10. 2-(2,4-Dichlorobenzylidene)-N-(3-chloro-4-ﬂuoro-
phenyl)hydrazinecarboxamide (4j). Yield 66%; m.p. 144–
146 C, IR (KBr) cm1: 3376 (NAH), 1674 (C‚O), 1548
(C‚N); (DMSO-d6) d ppm: 2.98 (s, 6H, N(CH3)2), 6.77–7.82
(m, 6H, aromatic), 7.99 (s, 1H, N‚CH), 9.06 (s, 1H, Ar–
NH), 10.57 (s, 1H, CONH); MS: m/z, M+ 360, M++1, 361,
M++2, 362; Anal. Calcd for C16H16ClFN4O: C, 46.43; H,
2.52; N, 11.65. Found: C, 46.64; H, 2.53; N, 11.66.
3.1.3.11. 2-[1-(4-Hydroxyphenyl)ethylidene]-N-(3-chloro-4-
ﬂuorophenyl)hydrazinecarboxamide (4k). Yield 66%; m.p.
180–182 C, IR (KBr) cm1: 3373 (NAH), 1686 (C‚O),
1528 (N‚C); (DMSO-d6) d ppm: 2.23 (s, 3H, CH3), 6.70–
7.82 (m, 7H, aromatic), 9.09 (s, 1H, Ar–NH), 10.59 (s, 1H,
CONH), 12.06 (s,1H, OH); MS: m/z, (M+) 321, M++1,
322, M++2, 323; Anal. Calcd for C15H13ClFN3O2: C,
56.00; H, 4.07; N, 13.06. Found: C, 56.02; H, 4.08; N, 13.08.
3.1.3.12. 2-[1-(4-Methoxyphenyl)ethylidene]-N-(3-chloro-4-
ﬂuorophenyl)hydrazinecarboxamide (4l). Yield 72%; m.p.
140–142 C, IR (KBr) cm1: 3369 (NAH), 1669 (C‚O),
1541 (C‚N); (DMSO-d6) d ppm: 2.23 (s, 3H, CH3), 3.79 (s,
3H, OCH3), 6.94–7.96 (m, 7H, aromatic), 9.05 (s, 1H, Ar–
NH), 9.83 (s, 1H, CONH); MS: m/z, M+ 321, M++1, 322,
M++2, 323; Anal. Calcd for C16H15ClFN3O2: C, 57.23; H,
4.50; N, 12.51. Found: C, 57.20; H, 4.48; N, 12.53.
3.1.3.13. 2-[1-(4-Chlorophenyl)ethylidene]-N-(3-chloro-4-ﬂuo-
rophenyl)hydrazinecarboxamide (4m). Yield 70%; m.p. 270–
272 C, IR (KBr) cm1: 3360 (NAH), 1679 (C‚O), 1549
(C‚N); (DMSO-d6) d ppm: 2.28 (s, 3H, CH3), 6.99–7.99 (m,
7H, aromatic), 9.00 (s, 1H, Ar–NH), 9.99 (s, 1H, CONH);
MS: m/z, M+ 335, M++1, 336, M++2, 337; Anal. Calcd
for C15H12Cl2FN3O: C, 52.56; H, 3.56; N, 12.35. Found: C,
52.58; H, 3.58; N, 12.36.
3.1.3.14. 2-[1-(4-Nitrophenyl)ethylidene]-N-(3-chloro-4-ﬂuo-
rophenyl)hydrazinecarboxamide (4n). Yield 70%; m.p. 186–188 C, IR (KBr) cm1: 3369 (NAH), 1675 (C‚O), 1579
(C‚N); (DMSO-d6) d ppm: 2.18 (s, 3H, CH3), 6.89–7.79 (m,
7H, aromatic), 9.05 (s, 1H, Ar–NH), 10.29 (s, 1H, CONH);
MS: m/z, M+ 350, M++1, 351, M++2, 352; Anal. Calcd
for C15H12ClFN4O3: C, 51.37; H, 3.45; N, 15.97. Found: C,
51.38; H, 3.46; N, 15.99.3.1.3.15. 2-[1-(4-Methylphenyl)ethylidene]-N-(3-chloro-4-ﬂuo-
rophenyl)hydrazinecarboxamide (4o). Yield 72%; m.p.
176–178 C, IR (KBr) cm1: 3367 (NAH), 1680 (C‚O),
1540 (C‚N); (DMSO-d6) d ppm: 2.02 (s, 3H, CH3), 2.27 (s,
3H, Ar–CH3), 6.51–7.93 (m, 7H, aromatic), 9.09 (s, 1H,
Ar–NH), 9.88 (s, 1H, CONH); MS: m/z, (M+) 319, M++1,
320, M++2, 321; Anal. Calcd for C16H15ClFN3O: C,
60.10; H, 4.73; N, 13.14. Found: C, 60.13; H, 4.75; N,
13.15.3.1.3.16. 2-(Furan-2-ylmethylidene)-N-(3-chloro-4-ﬂuoro-
phenyl)hydrazinecarboxamide (4p). Yield 68%; m.p. 158–
160 C, IR (KBr) cm1: 3377 (NAH), 1685 (C‚O), 1545
(C‚N); (DMSO-d6) d ppm: 6.51–7.73 (m, 6H, aromatic),
7.99 (s, 1H, N‚CH), 8.09 (s, 1H, Ar–NH), 9.18 (s, 1H,
CONH); MS: m/z, (M+) 281, M++1, 282, M++2, 283; Anal.
Calcd for C12H9ClFN3O2: C, 51.17; H, 3.22; N, 14.92. Found:
C, 51.19; H, 3.23; N, 14.93.4. Results and discussion
4.1. Chemistry
The title compounds (4a–p) were described in this study and
the reaction sequence for the synthesis is summarised in
Scheme 1. In the initial step 3-chloro-4-ﬂuorophenyl urea
(2) was synthesized from sodium cyanate and 3-chloro-4-
ﬂuoroaniline (1) in glacial acetic acid which was then
reﬂuxed with hydrazine hydrate in ethanol to obtain 3-
chloro-4-ﬂuorophenyl semicarbazides (3) followed by con-
densation with appropriate aldehydes or ketones in the
presence of ethanol and sodium acetate furnished the titled
compounds (4a–p). The yields of the titled compounds were
ranging from 58% to 74% after recrystallization with abso-
lute ethanol. The purity of the compounds was checked by
TLC using eluants chloroform-methanol (9:1) and elemental
analyses. Both the analytical and spectral data (IR, 1H
NMR) of all the synthesized compounds were in full agree-
ment with the proposed structures. In general, infra red spec-
tra (IR) revealed NAH, C‚O, and C‚N at 3366–3375,
1679–1686, and 1528–1541 cm1, respectively. In the Nuclear
Magnetic resonance spectra (1H NMR) the signals of the
respective protons of the prepared titled were veriﬁed on
the basis of their chemical shift, multiplicities and coupling
constants. The spectra showed a singlet at d 2.02–2.96 ppm
corresponding to CH3 group; singlet at d 3.79–3.80 ppm
corresponding to OCH3 group; multiplet at d 6.51–
8.38 ppm corresponding to aromatic protons; singlet at d
7.89–10.42 ppm corresponding to Ar–NH; singlet at d 7.96–
8.76 ppm corresponding to N‚CH; singlet at d 8.88–
11.52 ppm corresponding to CONH; singlet at d 10.67 ppm
corresponding to Ar-OH. The elemental analysis results were
within ±0.4% of the theoretical values.
Scheme 1 Protocol for synthesis.
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The investigation of antibacterial screening data revealed that
all the tested compounds showed good to low bacterial inhibi-
tion. The compound 4f showed good antibacterial inhibition
against Escherichia coli and Pseudomonas aeruginosa at 4 lg/
ml equivalents to standard Ciproﬂoxacin. The compounds 4d
and 4k showed moderate activity between 16 and 32 lg/ml,
rest of the compounds showed low antibacterial activity.
4.3. Antifungal activity
Antifungal screening data revealed that most of the com-
pounds showed moderate to low activity. The most active
compound of the series was 4g which showed fungal inhibition
against Aspergillus niger and Candida albicans at MIC of 4 and
8 lg/ml, respectively. The compounds 4h, 4i, 4l and 4o showed
moderate activities between 8 and 16 lg/ml, while rest of the
compounds showed low antifungal activity.
5. Conclusion
A series (4a–p) of semicarbazone derivatives were subjected for
the prediction of molecular properties before antimicrobial
screening. All the 16 compounds followed the Lipinski ‘‘Rule
of Five’’. The syntheses of semicarbazone derivatives were gov-
erned by treating aniline with sodium cyanate to obtain phenyl
urea (2) which was then reﬂuxed with hydrazine hydrate in eth-
anol to obtain 3-chloro-4-ﬂuorophenyl semicarbazides (3) fol-
lowed by condensation with appropriate aldehydes or ketones
in the presence of ethanol and sodium acetate furnished the
titled compounds (4a–p). All the titled compounds were
screened for antibacterial and antifungal activity as per the
standard protocol. On the basis of the results obtained from
antimicrobial screening it was found that compound 2-(4-
hydroxybenzylidene)-N-(3-chloro-4-ﬂuorolphenyl)hydrazine-
carboxamide (4f) was the most active compound that showed
good antibacterial activity while the compound 2-(4-methoxy-
benzylidene)-N-(3-chloro-4-ﬂuorolphenyl)hydrazinecarboxa-
mide (4g) was moderately active on fungal strains. Examiningclosely on substitutions, it may be concluded that the electron
releasing group such as –OH and electronegative group such as
–NO2 on the phenyl ring at position 4 showed good antibacte-
rial activity while the electron releasing group such as –OCH3
on phenyl ring at position 4 showed moderate antifungal activ-
ity. Further it may be concluded that the activity was more
pronounced if imine H was present on the semicarbazones.
6. Biological methods
6.1. Antibacterial screening
The synthesized title compounds (4a–p) were screened for anti-
bacterial activity against Staphylococcus aureus (NCIM 2079),
B. subtilis (NCIM 2439), E. coli (NCIM 5051) and P. aerugin-
osa (ATCC 10145) bacterial strains by disc-diffusion method
(Cruickshank et al., 1975; Collins, 1976). All the bacterial
strains were procured from National Chemical Laboratory,
Pune and American Type Culture Collection (ATCC) and
Gene Bank, Institute of Microbial Technology, Chandigarh,
India. Ciproﬂoxacin was used as a standard drug. Minimum
inhibitory concentrations (MICs) were determined by broth
dilution technique. The nutrient broth, which contained loga-
rithmic serially two fold diluted amount of the test compound
and controls was inoculated with approximately 5 · 105 c.f.u.
of actively dividing bacteria cells. The cultures were incubated
for 24 h at 37 C and the growth was monitored visually and
spectrophotometrically. The lowest concentration (highest
dilution) required to arrest the growth of bacteria was
regarded as minimum inhibitory concentration (MIC). The
minimum inhibitory concentrations are given in Table 2.
6.2. Antifungal screening
The synthesized title compounds (4a–p) were screened for anti-
fungal activity against A. niger (NCIM 1196) and C. albicans
(NCIM 3471) in DMSO by agar diffusion method (Khan,
1997; Varma, 1998). All the fungal strains were procured from
National Chemical Laboratory, Pune, India. The fungal
activity of each compound was compared with ﬂuconazole as
Table 2 Antimicrobial screening of the title compounds.
Compound Minimum inhibitory concentration (lg/ml)
Antibacterial Antifugal
S. aureus B. subtilis E. coli P. aeruginosa A. niger C. albicans
4a 64 128 64 256 128 128
4b 128 128 128 256 256 128
4c 32 64 32 64 128 64
4d 8 16 8 32 64 32
4e 32 32 32 64 128 256
4f 8 16 4 4 128 256
4g 128 128 64 128 4 8
4h 128 128 64 256 8 16
4i 256 256 256 512 8 8
4j 32 16 16 32 256 256
4k 8 16 8 16 128 128
4l 32 32 32 64 8 16
4m 64 128 128 256 128 128
4n 16 16 16 32 128 64
4o 256 256 128 256 16 16
4p 256 256 256 256 256 256
Ciproﬂoxacin 4 4 4 4 – –
Fluconazole – – – – 2 1
S866 M.J. Ahsan et al.standard drug. The nutrient broth, which contained logarith-
mic serially two fold diluted amount of test compound and
controls was inoculated with approximately 1.6–6 · 104 c.f.u./
ml. The cultures were incubated for 48 h at 35 C and the
growth was monitored. The lowest concentration (highest dilu-
tion) required to arrest the growth of the fungus was regarded
as minimum inhibitory concentration (MIC). The minimum
inhibitory concentrations are given in Table 2.Acknowledgments
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